Skip to content
Skip over generic navigation
Skip over primary navigation
Skip over visual
Skip over functional column
Most recently, we have invested in a new HPAPI lab that is run in accordance with current Good Manufacturing Practice (cGMP) regulations, and supports the synthesis of HPAPIs with an occupational exposure limit (OEL) as low as 5 ng/m³. This represents an important addition to our HPAPI offering; we already have the world’s largest HPAPI manufacturing capacity (170 m³), and can scale production up to a volume of almost 8,000 liters as required.
In terms of fermentation – another area of expertise for Evonik – we are currently investing in a multi-purpose fermentation plant with downstream processing (DSP) capabilities. At present, we have a total fermentation reactor volume of nearly 4,000 m³, and can assist from strain development to commercial manufacturing.
We are also making strides in the field of API conjugation. Evonik is at the forefront of various markets for mPEGs. Currently, we are investing in a dedicated mPEG kilo lab at our site in Hanau, Germany for highquality in PEG products.
Moreover, our customers reap the benefits of our continuous processes. We have a wealth of knowledge and experience in diverse types of continuous manufacturing, and the majority of Evonik´s products are produced using this method.